APTX Projected Dividend Yield

Aptinyx Inc ( OTCBB : APTX )

Aptinyx is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Co. focuses on targeting and modulating N-methyl-D-aspartate receptors, which are vital to normal and effective function of the brain and nervous system. Co.'s primary product, NYX-783 is in Phase 1 clinical development for the treatment of opioid use disorder, and in preclinical development for the treatment of alcohol use disorder.

11 YEAR PERFORMANCE RESULTS